ArticleEuropean heart journal. Case reports2025
Left atrial substrate modification in addition to pulmonary vein isolation using a novel circular variable loop pulsed field ablation catheter.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulsed field ablation (PFA) is a recently developed technology that causes tissue necrosis through electroporation and has been employed and validated for pulmonary vein isolation (PVI) in atrial fibrillation (AF) ablation. Only few devices have received a CE mark for this use and the Varipulse Case summary: A 73-year-old Caucasian woman with multiple cardiovascular risk factors presented with highly symptomatic paroxysmal AF and was scheduled to undergo PFA AF ablation using the new Varipulse catheter. The procedure was performed under deep sedation and the catheters were advanced through trans-septal puncture. 3D electroanatomic mapping of the left atrium showed significant anterior wall fibrosis. After PVI, substrate modification through an anterior mitral line (AML) approach was pursued. The AML was performed with additional PFA applications and successful bidirectional block was confirmed by pacing maneuvers without any procedural complications. The patient was discharged the following day, asymptomatic and in a state of well-being. Conclusion: Individual LA substrate modification, including linear lesion sets, can be delivered in addition to PVI using the novel Varipulse PFA catheter in patients with AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.